Liposome-based immunotherapy against autoimmune diseases: therapeutic effect on multiple sclerosis

Nanomedicine (Lond). 2017 Jun;12(11):1231-1242. doi: 10.2217/nnm-2016-0410.

Abstract

Aim: Based on the ability of apoptosis to induce immunological tolerance, liposomes were generated mimicking apoptotic cells, and they arrest autoimmunity in Type 1 diabetes. Our aim was to validate the immunotherapy in other autoimmune disease: multiple sclerosis.

Materials & methods: Phosphatidylserine-rich liposomes were loaded with disease-specific autoantigen. Therapeutic capability of liposomes was assessed in vitro and in vivo.

Results: Liposomes induced a tolerogenic phenotype in dendritic cells, and arrested autoimmunity, thus decreasing the incidence, delaying the onset and reducing the severity of experimental disease, correlating with an increase in a probably regulatory CD25+ FoxP3- CD4+ T-cell subset.

Conclusion: This is the first work that confirms phosphatidylserine-liposomes as a powerful tool to arrest multiple sclerosis, demonstrating its relevance for clinical application.

Keywords: autoimmunity; experimental autoimmune encephalomyelitis; immunotherapy; liposomes; multiple sclerosis.

MeSH terms

  • Animals
  • Autoantigens / administration & dosage*
  • Autoantigens / immunology
  • Autoantigens / therapeutic use
  • Female
  • Immunotherapy / methods*
  • Liposomes / chemistry*
  • Mice, Inbred C57BL
  • Multiple Sclerosis / immunology
  • Multiple Sclerosis / therapy*
  • Myelin-Oligodendrocyte Glycoprotein / administration & dosage*
  • Myelin-Oligodendrocyte Glycoprotein / immunology
  • Myelin-Oligodendrocyte Glycoprotein / therapeutic use
  • Peptides / administration & dosage*
  • Peptides / immunology
  • Peptides / therapeutic use
  • Phosphatidylserines / chemistry*
  • T-Lymphocytes, Regulatory / immunology

Substances

  • Autoantigens
  • Liposomes
  • Myelin-Oligodendrocyte Glycoprotein
  • Peptides
  • Phosphatidylserines